Roger Stupp

TL;DR: Malignant glioma comprises glioblastoma [World Health Organization (WHO) grade IV], anaplastic astrocytoma (WHO grade III), mixed anaPLastic oligoastrocyToma and anapl Plastic oligodendroglioma ( WHO grade III).

TL;DR: Prospective trials using specific criteria and standardized methods to evaluate tissue biomarkers are required to find predictors of EGFR inhibitors activity in high-grade glioma patients.

TL;DR: The pharmacological approach to epilepsy requires a multidisciplinary approach, specifically in a setting of rapidly increasing choices of agents both to treat cancer and cancer-associated epilepsy.

TL;DR: It is demonstrated that high intratumoral IDO1 mRNA levels correlate with a poor GBM patient prognosis and that future efforts aimed at increasing T-cell–mediated effects against GBM should consider combinatorial approaches that coinhibit potential T- cell–mediated IDO 1 enhancement during therapy.

TL;DR: The NANO scale is designed to combine with radiographic assessment to provide an overall assessment of outcome for neuro-oncology patients in clinical trials and in daily practice and complements existing patient-reported outcomes and cognition testing to combine for a global clinical outcome assessment of well-being among brain tumor patients.